Medical Devices APAC

APAC Hormone Testing at Home Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Hormone Testing at Home Market Industry Trends and Forecast to 2034: Segmented by (Hormone, Sample, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $142.0 Mn Placeholder estimate
Estimate 2025 $158.4 Mn 18.7% of the global market
Projected 2034 $425.4 Mn 168.5% Adds $267.0 Mn over 9 forecast years
CAGR 2025–2034 11.6% Faster than 64% of 173 Medical Devices markets here
Key players 5 Companies profiled
  • APAC is 18.7% of the global market.
  • Among regions, the largest is North America at $355.7 Mn.
  • Fastest growing: Africa at 11.8% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$267.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hormone Testing at Home Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $142.0 Mn — —
2025 (base) $158.4 Mn +$16.5 Mn —
2026 (forecast) $176.8 Mn +$18.4 Mn +11.6%
2027 (forecast) $197.3 Mn +$20.5 Mn +24.5%
2028 (forecast) $220.2 Mn +$22.9 Mn +39%
2029 (forecast) $245.7 Mn +$25.5 Mn +55.1%
2030 (forecast) $274.2 Mn +$28.5 Mn +73.1%
2031 (forecast) $306.1 Mn +$31.8 Mn +93.2%
2032 (forecast) $341.6 Mn +$35.5 Mn +115.6%
2033 (forecast) $381.2 Mn +$39.6 Mn +140.6%
2034 (forecast) $425.4 Mn +$44.2 Mn +168.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $847.0 Mn
  2. US $379.4 Mn
  3. North America $355.7 Mn
  4. APAC (this report) $158.4 Mn
  5. Europe $135.3 Mn
  6. Canada $65.0 Mn
  7. China $61.6 Mn
  8. Japan $45.4 Mn
  9. Germany $32.0 Mn
  10. Latin America $33.3 Mn
  11. Middle East $31.4 Mn
  12. UK $22.9 Mn
  13. France $21.5 Mn
  14. Brazil $21.9 Mn
  15. Italy $17.2 Mn
  16. Ecuador $17.2 Mn
  17. Spain $16.3 Mn
  18. India $16.0 Mn
  19. Mexico $14.4 Mn
  20. Saudi Arabia $13.7 Mn
  21. Africa $12.5 Mn
  22. Australia $11.7 Mn
  23. New Zealand $8.2 Mn
  24. Russia $7.5 Mn
  25. South Africa $5.7 Mn
  26. UAE $4.8 Mn
  27. Egypt $2.4 Mn
  28. Philippines $2.1 Mn
  29. Hong Kong $1.4 Mn
  30. Malaysia $1.2 Mn
  31. Singapore $1.1 Mn
  32. Thailand $1.1 Mn
  33. Kenya $0.6 Mn

Report snapshot

APAC Hormone Testing at Home Market Analysis at a glance
Market size, 2025$158.4 Mn placeholder estimate
Forecast, 2034$425.4 Mn placeholder estimate
Growth (CAGR), 2025–203411.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsHormone, sample and end user (see all)
Key playersEverlywell, LetsGetChecked, Thorne, Mira, Hims & Hers Health (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Hormone Testing at Home Market Analysis Executive Summary

At-home hormone tests measure hormones such as estrogen, thyroid, cortisol and testosterone from finger-prick blood or saliva.

Key segments of the hormone Testing at Home market include hormone (Female Sex Hormones, Thyroid and Cortisol) and sample (Blood, Saliva and Urine).

Bar chart: Asia Pacific Hormone Testing at Home market size, 2024–2034, placeholder estimates. $142.0 Mn in 2024, $158.4 Mn in 2025 and $425.4 Mn in 2034, 11.6% CAGR.
Asia Pacific Hormone Testing at Home market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Hormone Testing at Home Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the hormone Testing at Home market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the hormone Testing at Home market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the hormone Testing at Home market.

Competitive Landscape for Hormone Testing at Home Market in APAC

The hormone Testing at Home market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hormone Testing at Home Market in APAC

Hormone Testing at Home in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how hormone Testing at Home products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hormone Testing at Home right now, from free public sources.

Latest research 4 papers since 2021 (worldwide)

  1. Association Between Hormone Variability and Anaerobic Performance in Recreationally Active Women: An Exploratory Study Using Mixed-Effect Location Scale Models. Journal of strength and conditioning research, 2026
  2. A Novel Approach to Characterization of the Female Hormone Profile: Feasibility and Research Application of Daily At-Home Urine Hormone Monitoring. Medicine and science in sports and exercise, 2026
  3. Menstrual tracking technologies and fertility: evaluating accuracy, utility, and impact on time to pregnancy. Fertility and sterility, 2026
  4. Evaluation of at-home serum anti-Müllerian hormone testing: a head-to-head comparison study. Reproductive biology and endocrinology : RB&E, 2022
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hormone Testing at Home in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Hormone Testing at Home market in Asia Pacific?
Placeholder estimate: about $158.4 Mn in 2025, rising to about $425.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Hormone Testing at Home market in Asia Pacific growing?
Placeholder estimate: about 11.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Hormone Testing at Home market report cover?
The report splits the market by hormone (Female Sex Hormones, Thyroid, Cortisol, Testosterone), sample (Blood, Saliva, Urine) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Hormone Testing at Home market?
Key players include Everlywell, LetsGetChecked, Thorne, Mira and Hims & Hers Health.
What is driving the Hormone Testing at Home market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the hormone Testing at Home market. New products designed around women's biology and digital care are improving access.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Hormone Testing at Home in APAC? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Women's Health Supplements: A Growing FocusAnaemia affects about half a billion women worldwide, and folic acid before pregnancy prevents serious birth… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Back to Catalogue
Keep exploring

Related Medical Devices reports in APAC

See all
Same topic, other categories

Related on women's health and diagnostics and lab testing

See the topic